Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 36381-36390 Newer>

The Motley Fool May 20, 2009 Alyce Lomax	Target's Quarter Was No Surprise Target has failed to stir up customer traffic, so maybe its historical "cheap chic" reputation has struck many shoppers as too chic and not cheap enough.
The Motley Fool May 20, 2009 Brian Orelli	Clinical Trial Positive, Stock Not So Much Isis and Genzyme hit a homer with their cholesterol drug, mipomersen, but they'll need another big play to win the game.
The Motley Fool May 20, 2009 Rick Aristotle Munarriz	E-House Builds Momentum in China Shares of China's E-House, the nation's leading real estate agency, rise after the real estate specialist posted better-than-expected first-quarter results and a healthy near-term outlook.
The Motley Fool May 20, 2009 Chris Jones	This Recession Just Tickles TJX TJX Companies, which operates T.J. Maxx, Marshalls, and a variety of other off-price clothing and home fashion retailers, seems tailor-made for difficult economic conditions.
The Motley Fool May 20, 2009 Rick Aristotle Munarriz	The Stream Rises for Netflix and Microsoft The video-rental specialist serves up more movies for Vista users.
The Motley Fool May 20, 2009 Rebecca Vestal	Under Armour Is Everywhere Under Armour is gaining ground in the athletic apparel market.
The Motley Fool May 20, 2009 Rich Smith	This Just In: Upgrade or Downgrade With just two weeks to go before its new "Pre" cell phone hits the street, Needham & Co. slaps Palm with an "underperform" rating.
The Motley Fool May 20, 2009 Matt Koppenheffer	Can Anything Save MGM Mirage? Will the CityCenter extravaganza help the gaming company conquer debt?
The Motley Fool May 20, 2009 Tim Beyers	What Kumo Must Do to Beat Google Microsoft will next week make public the next-generation version of its Live Search engine, code-named "Kumo."
The Motley Fool May 20, 2009 Brian Orelli	Johnson & Johnson Tries to Pull a Travolta Johnson & Johnson seems to be making a comeback, after its drug-eluting stent market share fell precipitously to just 15% in the first quarter.
<Older 36381-36390 Newer> Return to current articles.